Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.400
-0.020 (-1.41%)
At close: Dec 5, 2025, 4:00 PM EST
1.380
-0.020 (-1.43%)
After-hours: Dec 5, 2025, 7:30 PM EST
Lexicon Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Lexicon Pharmaceuticals stock ranges from a low of $1.00 to a high of $6.00. The average analyst price target of $3.23 forecasts a 130.71% increase in the stock price over the next year.
Price Target: $3.23 (+130.71%)
Analyst Consensus: Buy
* Price targets were last updated on Sep 2, 2025.
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +185.71% | Sep 2, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $1.2 → $1.9 | Strong Buy | Maintains | $1.2 → $1.9 | +35.71% | Aug 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +185.71% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +185.71% | Mar 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +328.57% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
48.68M
from 31.08M
Increased by 56.61%
Revenue Next Year
17.59M
from 48.68M
Decreased by -63.87%
EPS This Year
-0.17
from -0.63
EPS Next Year
-0.26
from -0.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 53.7M | 37.8M | ||||
| Avg | 48.7M | 17.6M | ||||
| Low | 43.4M | 5.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 72.6% | -22.3% | ||||
| Avg | 56.6% | -63.9% | ||||
| Low | 39.7% | -87.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.17 | -0.20 | ||||
| Avg | -0.17 | -0.26 | ||||
| Low | -0.18 | -0.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.